Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Ultragenyx Pharmaceutical IncRARE | $25.32 | Strong Buy | $83.00 | +227.80% | 16 hours ago | |
Analyst RankingTop 5% #259 out of 5497 analysts Average Return+24.52% Win Rate51%74 out of 145 Risk vs RewardPoor Good Analyst ColorCanaccord Genuity's Whitney Ijem raised their price target on Ultragenyx Pharmaceutical (NASDAQ: RARE) by 2.5% from $81 to $83 on 2026/08/20. The analyst maintained their Strong Buy rating on the stock. Ijem said their price target hike was catalyzed by the expected FDA approval of Ultragenyx Pharmaceutical's gene therapy for glycogen storage disease type Ia (GSDIa) as Genglycos (pariglasgene brecaparvovec-opnr; formerly DTX401). | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.